LYRA · Lyra Therapeutics, Inc.
$0.50
+0.00 (+0.00%)
At close · Jul 28
Going-concern doubt
— flagged Mar 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern”View the 10-K filed Mar 31, 2026
Market Cap
$887,441
Shares
1.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.50
Open$0.50
Day$0.50–0.50
52W$0.00–8.75
Avg vol 30d11K
Short int5K · 0.3% float · 1.0d
Short vol2%
Last earningsJun 2, 2025
DataMay 2020–Jul 2026
Filing10-K · Mar 31
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Mar 31, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−76%
below
Price vs 50-day avg
−20%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−75%
trailing
YTD return
−84%
this year
Relative strength
−82%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-96% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.28% of float · ▼ -20.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Squeeze score
20
low risk · 0–100
Fundamentals
Revenue growth
−74%
Y/Y
EPS growth
+74%
Y/Y
Free cash flow
$-29.0M
Balance sheet
$15.9M
net cash
Quant / Vol
risk profile
Volatility
135%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
19.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−76%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-96% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.28% of float · ▼ -20.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $0
Now $1 · 6%
52-wk high $9
vs 200-day avg -76%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LYRA
this stock
Lyra Therapeutics, Inc.
|
$887,441 | -83.8% | -1.5% | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
1
- % held
- 5.9%
- Net QoQ
- -138.6K sh
- Top holder
- SABBY MANAGEMENT, LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LYRA | -3.9% | -16.1% | -74.8% | -28.1% | -83.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -2.9% | -16.1% | -82.2% | -27.3% | -92.4% |